Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pinatuzumab vedotin
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pinatuzumab vedotin is an investigational antibody-drug conjugate (ADC) developed for the treatment of B-cell malignancies, particularly non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL)[1][4][8]. It consists of a humanized monoclonal antibody targeting CD22, a cell surface antigen expressed on most B-cell lineage cells, linked via a protease-cleavable linker to monomethyl auristatin E (MMAE), a potent antimicrotubule agent[2][6]. Upon binding to CD22 on tumor cells and internalization, the linker is cleaved by intracellular proteases, releasing MMAE inside the cell. MMAE then inhibits tubulin polymerization, disrupting mitosis and inducing apoptosis in malignant B-cells[6]. Pinatuzumab vedotin was developed by Genentech/Roche in collaboration with Seattle Genetics/Seagen. Clinical development has been discontinued for its main indications[4].
- Other names
- ACD22-VCMMAEACD-22-VCMMAEACD 22-VCMMAEAnti-CD22-MCC-DM1Anti-CD-22-MCC-DM1Anti-CD 22-MCC-DM1Anti-CD22 antibody–drug conjugate
02
Targets
CD22 (Cluster of Differentiation 22)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pinatuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pinatuzumab vedotin.